Ad Scientiam
French tech company | Builders Republic
About
Ad Scientiam designs and clinically validates digital biomarkers from patients' smartphones for the remote monitoring of severe and disabling chronic diseases (multiple sclerosis with MSCopilot, autoimmune neurological diseases, rare diseases). Its digital medical devices turn real-life collected data into objective indicators used in clinical research and routine care.
Key facts
- Status
- Active
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Private Equity Round
- Founded
- 2013
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
Operations
- Private Equity Round · 2025
Investors
- Techlife Capital
Notes
Techlife Capital entre au capital en minoritaire en novembre 2025.